

Ha

Kn

Li

SS

SF

SH

Wa

WL

Wi



PAN MERSEY AREA PRESCRIBING COMMITTEE
PRESCRIBING POLICY STATEMENT
REF: PS182 FINAL
APC BOARD DATE: 24 MAY 2017



Pan Mersey
Area Prescribing Committee

IXEKIZUMAB solution for injection (Taltz® ▼) for Plaque Psoriasis

RED

The Pan Mersey Area Prescribing Committee recommends the prescribing of IXEKIZUMAB solution for injection (Taltz® ▼) in specialist settings only, for treating plaque psoriasis in accordance with NICE TA442.

NICE technology appraisal (TA) 442¹ recommends ixekizumab as an option for treating plaque psoriasis in adults, only if:

- > the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10
- > the disease has not responded to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them, and
- > the company provides the drug with the discount agreed in the patient access scheme.

Ixekizumab treatment should be discontinued at 12 weeks if the psoriasis has not responded adequately. An adequate response is defined as:

- > a 75% reduction in the PASI score (PASI 75) from when treatment started **or**
- > a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from when treatment started.

Prescribing and monitoring of therapy must be retained by a specialist in the management of plaque psoriasis.

NICE estimates the cost of implementing this TA as £42,743 per 100,000 population by 2021/22. It is estimated that 230 patients in England will be treated with ixekizumab in 2017/18 and so the cost impact per 100,000 population is likely to be minimal in the first year. All estimates are based on NHS list price so actual costs may differ once the patient access scheme (PAS) discount has been applied (commercial in confidence).

This guidance is not intended to affect the position of patients whose treatment with ixekizumab was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

Reference:

1. National Institute for Health and Care Excellence. Technology Appraisal guidance (TA) 442: Ixekizumab for treating moderate to severe plaque psoriasis, April 2017. Accessed 28 April 2017 at: <https://www.nice.org.uk/guidance/ta442>

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.